1. Louis DN, Ohgaki H, WiestlerOD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P.(2007) The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol, 114: 97-109.
2. Vitanovics D, Sipos L, ÁfraD.(2002) BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic asztrocitomas and glioblasztomas.Neoplasma, 49:
342-345.
3. Áfra D, Osztie É, Sipos L, Vitanovics D.(1999) BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic asztrocitomas and glioblasztomas.Br J Neurosurg, 13: 299-305.
4. Áfra D, Sipos L, Vitanovics D.(2002)Chemotherapy of recurrent supratentorial malignant gliomas (phase II study).Ideggyogy Sz, 55(1-2): 38-44.
5. Sipos L,VitanovicsD, Áfra D.(2002) Treatment of reccurent malignant gliomas with temozolomide.Orv Hetil, 19: 1200-204.
6. Sipos L, Vitanovics D, Afra D.(2004) Temozolomide chemotherapy of patients with recurrent anaplastic asztrocitomas and glioblasztomas.Ideggyogy Sz, 57(11-12): 349-9.
7. Hanzély Z, Polgár C, Fodor J,Brucher JM, Vitanovics D, Mangel LC, Afra D. (2003) Role of early radiotherapy in the treatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients.J Neurooncol, 63: 305-12.
8. Vitanovics D, Bálint K, Hanzély Z, Banczerowski P, Áfra D. (2010) Ependymoma in adults: surgery, reoperation and radiotherapy for survival.Pathol Oncol Res, 16: 93-99.
9. Vitanovics D, Áfra D, Nagy G, Hanzely Z, Turányi E, Banczerowski P.
(2014)Symptomatic Subependymomas of The Ventricles. Review of twenty consecutive cases. Ideggyogy Sz, 67(11–12): 415–419.
10. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA.(1980) Randomised comparisons
85
of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med, 303: 1323 -29.
11. Stewart LA.(2002) Chemotherapy in adult hight grade glioma: a systematic review and meta-analysis of induvidual patient data from 12 randomised trials. Lancet, 359:
1011-18.
12. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO;on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10: 459-66.
13. Vitanovics D, Áfra D. (1998) Glioblasztoma Multiforme: A Survey of history and clinical data of 1478 operated patients. Ideggy Szle, 51 (7-8): 236-242
14. Áfra D, Vitanovics D.(1998)Glioblasztoma Multiforme II: Results of surgery and surgery plus postoperative treatment of 1478 operated patients.Ideggy Szle, 52(1-2): 5-10.
15. Levin VA, Wara MW, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB.(1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg, 63: 218 - 223.
16. Cairncross J, Gregory MD, Macdonald DR.(1992) Aggressive Oligodendroglioma:
A Chemosensitive Tumor. Neurosurg, 31: 78-82.
17. Gutin PH, Posner JB.(2000) Neuro-oncology: diagnosis and management of cerebral gliomas-past, present, and future. Neurosurg, 47(1): 1-8.
86
18. Recht LD, Lew R, Smith Th.(1992) Suspected low‐grade glioma: Is deferring treatment safe? Ann Neurol, 31(4): 431-436.
19. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB. (2002) Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma. European Organisation for Research and Treatment of Cancer Brain Tumour Cooperative Group and Radiotherapy Cooperative Group. J Clin Oncol 20(8): 2076-2084.
20. Shaw GE, WisoffHJ.(2003) Prospective clinical trials of intracranial low-grade glioma in adults and children. NeuroOncol, 5: 153-160.
21. Kaal E, Vecht CJ. (2004) The management of brain edema in brain tumors. Curr Opin Oncol, 16: 593-600.
22. Galicich JH, French LA, Melby JC.(1961) Use of Dexamethason in the Treatment of Cerebral Oedema, Resulting from Brain Tumors and Brain Surgery. Am Practitioner, 12: 169-174.
23. Renaudin J, Fewer D, Wilson CB, Boldrey J, Calogero FM, Enot JK.(1973) Dose dependency of Decadron in patients with partially excised brain tumors. J Neurosurg, 39: 302-305.
24. Andersen C.Steroids in Neurosurgery. Springer Verlag,Berlin, Heidelberg, New York, 1996:129-133.
25. Miller JD, Sakalas R, Ward JD, Young HF, Adams WE, Vries JK, Becker DP.(1977) Metilprednisolone Treatment in Patients with Brain Tumors. Neurosurg, 1(2): 114-117.
26. Lieberman A, LeBrun Y, Glass P,Goodgold A, Lux W, Wise A, Ransohoff J.(1977) Use of high-dose corticosteroids in patients with inoperable brain tumors. J Neurol Neurosurg Psychiatry, 40: 678-82.
27. Weiner HL, Rezai AR, Cooper PR.(1993) Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids. Neurosurg, 33: 40-43.
87
28. Dietrich J, Rao K, Pastorino S, Kesari S. (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol, 4(2): 233-242
29. Jamous MA.High-dose Metilprednisolon for Malignant Gliomas: Safety and Side effects. In Capideo R (ed), Steroids in Diseases of the Central Nervous System, John Wiley and Sons Ltd, Chichester, 1998 : 113-122.
30. Edwards DF, Chen YW, Diringer MN.(1995) Unified Neurological Stroke Scale Is Valid in Ischemic and Hemorrhagic Stroke. Stroke, 26: 1852-1858.
31. Kleihues P, Burger PC, Scheithauer BW.(1993) The new WHO classification of brain tumours. Brain pathol, 3(3): 255-268.
32. Cox DR.(1972) Regression models and life tables. J R Statist Soc B, 34: 187-220.
33. MacdonaldDR, Cascino TL, ScholdSC Jr, Cairncross JG.(1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol, 8: 1277-1280.
34. Kaplan EL, Meier P. (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc, 6: 457-481.
35. French LA, Galicich JH.(1964) The Use of Steroids for Control of Cerebral Edema.
Clinical Neurosurgery, 10: 212-223.
36. Pilkington GJ, Darling JL, Lantos PL, Thomas DG. (1983) Cell lines (VMDk) derived from a spontaneous murine astrocytoma. Morphological and immunocytochemichal characterisation. J Neurol Sci, 62: 115-139.
37. Green SB, Byar DP, Walker MD,Pistenmaa DA, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, Paoletti P, Ransohoff J 2nd, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA. (1983) Comparisons of Carmustine, Procarbazine and high dose Metilprednisolon as additions to surgery and radiotherapy for treatment of malignant glioma. Cancer Treat Rep, 67: 121-132.
38. Andersen C, Haselgrove JC, Doenstrup S,Astrup J, Gyldensted C.(1993) Resorption of Peritumoral Edema in Cerebral Glioma During Dexamethasone Treatment Evaluated by NMR Relaxation Time Imaging. Acta Neurochir , 122: 218-224.
88
39. Chen CT, Mackic JB, McComb JG,Giannotta SL, Weiss MH, Zlokovic BV. (1996) Cellular Uptake and Transport of Metilprednisolon at the Blood-Brain Barrier.
Neurosurg, 38: 348-354.
40. Hall ED. (1992) The neuroprotective pharmacology of metilprednisolon. J Neurosurg, 76: 13-22.
41. Leigarda R, Sierra J, Pardal C, Zambrano D.(1985) Effect of Large Doses of Metilprednisolon on Supratentorial Intracranial Tumors. Eur J Neurol, 24: 23-32.
42. Davis L, Martin J, Goldstein SL, Ashkenazy M.(1949) A study of 211 patients with verified glioblasztoma multiforme. J Neurosurg, 6: 33-44.
43. Frankel SA, German WJ.(1958) Glioblastome multiforme review of 219 cases with regard to natural history, pathology, diagnostic methods and treatment. J Neurosurg, 15:
489-503.
44. Roth JG, Elvidge AR. (1960)Glioblasztoma multiforme: a clinical survey. J Neurosurg, 17: 736-750.
45. Jelsma R, Bucy PC.(1967) The treatment of glioblasztoma multiforme of the brain.
JNeurosurg, 27: 388-400.
46. Jelsma R, Bucy PC. (1969) Glioblastome multiforme. Its treatment and some factors effecting survival. Arch Neurol, 20: 161-171.
47. Choi NW, Schuman LM, Gullen WH.(1970) Epidemiology of primary central nervous system neoplasms : Mortality from primary central nervous system neoplasms in Minnesota. Am J Epidemiol, 91: 238-259.
48. Miller PJ, Hassanein RS, Giri PG, Kimler BF, O'Boynick P, Evans RG.(1990) Univariate and multivariate statistical analysis of high-grade gliomas: The relationship of radiation dose and other prognostic factors. Int J Radiat Oncol Biol Phys, 19: 275-280.
49. Weir B.(1973) The relative significance of factors affecting postoperative survival in asztrocitomas grades 3 and 4. J Neurosurg, 38: 448-452.
89
50. Stage WS, Stein JJ.(1974) Treatment of malignant asztrocitomas. Am J Radiology, 120: 7-19.
51. Burger PC, Green SB.(1987) Patient age, histologic features, and length of survival in patients with glioblasztoma multiforme. Cancer, 59: 1617-1625.
52. Duncan GG, Goodman GB, Ludgate CM, Rheaume DE.(1992) The treatment of adult supratentorial high grade asztrocitomas. J Neurooncol, 13: 63-72.
53. Vecht CJ, Avezat CJJ, van Putten WLJ, Eijekenboom WMH.(1990) The influence of the extent of surgery on the neurological function and survival in malignant glioma.
A retrospective analysis in 243 patients. J Neurol Neurosurg Psych, 53: 466-471.
54. Nazzaro JM, Neuwelt EA.(1990) The role of surgery in the management of supratentorial intermediate and high grade asztrocitomas in adults. J Neurosurg, 73:
331-344.
55. Walker MD, Gehan EA.(1976) Clinical studies in malignant glioma and their treatment with the nitrosoureas. Cancer Treat Rep, 60: 713-716.
56. Cohadon F, Aouad N, Rougier A,Vital C, Rivel J, Dartigues JF.(1985) Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neurooncol, 3: 105-111.
57. Shapiro WR. (1986) Therapy of adult malignant brain tumors: what have the clinical trials tought us. Semin Oncol, 13: 38-45.
58. Smith DF, Hutton JL, Sandemann D,Foy PM, Shaw MD, Williams IR, Chadwick DW.(1991) The prognosis of primary intracerebral tumors presenting with epilepsy: the outcome of medical and surgical management. J Neurol Neurosurg Psych, 54: 915-920.
59. Wigner MJ, MacDonald DR, Cairncross JG.(1989) Supratentorial anaplastic asztrocitomas in adults. The prognostic importance of extent of resection and prior low/grade glioma. J Neurosurg, 71: 487-493.
90
60. Stenning SP, Freedman LS, Bleehen NM. (1990) Prognostic factors for high-grade malignant glioma: Development of prognostic index. A report of the Medical Research Council Brain Tumour Working Party. J Neurooncol, 9(1): 47-55.
61. Elliot TE, Dinapoli RP, O’Fallon JR, Krook JE, Earle JD, Morton RF, Levitt R, Tschetter LK, Scheithauer BW, Pfeifle DM, Twito DI, Nelimark RA. (1997) Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade asztrocitoma. J Neurooncol, 33: 239-250.
62. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T.(1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurg, 41: 44-49.
63. Goldsmith MA.(1974) Glioblasztoma multiforme – a review of therapy. Cancer Treat Rev, 1: 153-165.
64. Kelly KA, Kirkwood JM, Kappy DS. (1984)Glioblasztoma multiforme: pathology, natural history and treatment. Cancer Treat Rev, 11: 1-26.
65. Shapiro WR.(1998) The Therapy of Primary Brain Tumors. BNI Quarterly. 14(2):
4-14.
66. Albert FK, Forsting M, Sartor K, Adams HP, Kunze S.(1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurg, 34: 45-60.
67. Kreth FW, Warnke PC, Scheremet R, Ostertag CB.(1993) Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblasztoma multiforme. J Neurosurg, 78: 762-766.
68. Devaux BC, O’Fallon JR, Kelly PJ.(1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg, 78: 767-775.
69. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS.(1993) Influence of location and extent of resection
91
on survival of patients with glioblasztoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phy, 26: 239-244.
70. Bouchard J.(1969) Radiation therapy in the management of primary brain tumors.
Annals of New York Academy of Science, 159: 563-570.
71. Lindgren M.(1958) On tolerance of brain tissue and sensivity of brain tumors to irradiation. Acta Radiol, Suppl.170.
72. Leibel SA, Sheline GE.(1987) Radiation therapy for neoplasms of the brain. Review Article. J Neurosurg, 66: 1-22.
73. Walker MD, Strike TA, Sheline GE.(1979) An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiation Oncol Biol Phys, 5: 1725-1731.
74. Woodhall B, Hall K, Mahaley Jr SG, Jackson J.(1959) Chemotherapy of brain cancer: experimental and clinical studies in localized hypothermic cerebral perfusion.
Ann Surg, 150: 640-652.
75. Owens G, Javid R, Belmusto L, Bender M, Blau M.(1965) Intraarterial vincristine therapy of primary gliomas. Cancer, 18: 756-760.
76. Gorácz I.(1969) The combined treatment of glioblasztoma multiforme. Minerva Neurochir, 13: 248-250.
77. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA.(1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg, 49: 333-343.
78. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D.(1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurol, 44: 1479-1483.
92
79. Áfra D, Kocsis B, Dobay J, Eckhardt S. (1983) Combined radiotherapy and chemotherapy with dibromodulcitol and CCNU in postoperative treatment of malignant gliomas. J Neurosurg, 59(1): 106-110.
80. Áfra D, Kocsis B, Kerpel-Fronius S, Eckhardt S.(1986) Dibromoducitol-based combined postoperative chemotherapy of malignant asztrocitomas and glioblasztomas. J Neurooncol, 4: 65-70.
81. Stupp R, Hegi M, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials.(2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblasztoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol, 10: 459-66.
82. EORTC 26053-22054 Intergroup trial. CATNON trial.
http://clinicaltrials.gov/ct2/show/NCT00626990.
83. Wedge SR, Porteous JK, Glaser MG,Marcus K, Newlands ES. (1997) In vitro evaluation of temozolomide combined with X-irradiation. Antocancer Drug, 8: 92-97.
84. Hegi ME, Liu L, Herman JG,Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR.
(2008) Correlation of O6-methylguanine methyltransferase (MGMT) with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol, 26: 4189-4199.
85. Turányi E., Hanzély Z., Bálint K., Reiniger L. (2013) A patológus szerepe a központi idegrendszer tumorainak diagnosztikájában, a terápiatervezésben.Prognosztikus és prediktív markerek vizsgálata.Magyar Onkológia, 57: 215–221.
93
86. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DTW, Collins VP.(2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas, NeuroOncol, 11: 341–347.
87. Yan H, Parsons DW, Jin G, McLendon R, Rasheed A, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD.(2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med, 360: 765–773.
88. Levine VA.(1999) Chemotherapy for brain tumours of astrocytic and oligodendroglial lineage: The past decade and where we are heading. Neuro-Oncol, 1:
69-80.
89. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'NeillAM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA.(1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group, J Clin Oncol, 17: 2762-2771.
90. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.
(2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 83: 588-593.
91. Hildebrand J, De Witte O, Sahmoud T.(1998) Response of recurrent glioblasztoma and anaplastic asztrocitoma to dibromodulcitol, BCNU and procarbazine. JNeurooncol, 37: 155-60.
92. Levin VA, Prados MD.(1992) Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol, 10: 776-71.
93. Prados MD, Gutin PhH, Phillips TL,Wara WM, Larson DA, Sneed PK, Davis RL, Ahn DK, Lamborn K, Wilson CB.(1992) Highly anaplastic asztrocitoma: A review of
94
357 patients treated between 1977 and 1989. Int J Radiation Oncology Biol Phys, 23: 3-8.
94. Kyritsis AP, Yung WKA, Bruner J,Gleason MJ, Levin VA.(1993) The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurg, 32: 365-370.
95. Bower M, Newlands ES, Bleehen NM,Brada M, Begent RJH, Calvert I, Colquhoun I, Lewis P, Brampton MH. (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol, 40: 484-488.
96. Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F. (2001) Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol, 19: 2449-2455.
97. Glioma Meta-analysis Trialists Group. (2002) Chemotherapy in adult high grade glioma: a systematic review and meya-analysis of individual patient from 12 trials.The Lancet, 359: 1011-8.
98. Sipos L, Áfra D. (1997) Re-operations of supratentorial anaplastic asztrocitomas.
Acta Neurochir, 139: 99-104.
99. Brandes AA, Vastola F, Basso U,Berti F, Pinna G, Rotilio A, Gardiman M, Scienza R, Monfardini S, Ermani M.(2003) A prospective study on glioblastoma in the eldery.
Cancer, 97: 657-62.
100.Morantz EA.Low grade asztrocitoma In: Laws JR, Kaye EH. Brain Tumours.
Edinbourgh : Churchill Livingstone, 1995: 433-448.
101. Low grade asztrocitomas may arise from different astrocyte lineages. Piepermeier JM, Fried I, Makuch R. 1993., Neurosurgery, 33. kötet, old.: 627-32.
102. Guthrie BL, Laws JR ER. Management of supratentorial low-grade gliomas. In:
Laws ER, Karim ABMF. GLIOMA Principals and Practice in Neuro-oncology. Berlin : Springer, 1991: 75-92.
95
103. Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lemaire JJ, Plagne R, Rozan R.(1994) Low grade supratentorial astrocytoma management and prognostic factors.Cancer, 73: 1937-45.
104. Piepermeier J, Christopher S, Spencer D,Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R.(1996) Natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurg, 38: 872-9.
105. Thomas DGT, McKeran RO. Clinical manifestation of brain tumours. In:Thomas DGT. Neurooncology, Primary Malignant Brain Tumours. London : Edward Arlnod, 1990.
106. North CA, North BA, Epstein JA,Piantadosi S, Wharam MD. (1990) Low grade cerebral astrocytomas - Survival and Quality of life after radiation therapy. Cancer, 66:
6-14.
107. Bartolomei JC, Cristopher S, Vives K,Spencer DD, Piepmeier JM.(1997) Low-grade glioma of chronic epilepsy: distinct clinical and pathological entity. J Neurooncol, 34: 79-84.
108. Cairncross JG, Laperrier NJ.(1989) Low-grade glioma to treat or not to treat? Arch Neurol, 46: 1238-9.
109. Shapiro WR.(1992) Low-grade gliomas; when to treat? Ann Neurol, 31: 437-8.
110. Piepermeier JM.(1997) Criteria for patient selection: low-grade gliomas.Clin Neurosurg, 44:51-62.
111. Vecht, CJ.(1993) Effect on age on treatment decision in low-grade glioma. J Neurol Neurosurg Psych, 56: 1259-64.
112. Franzini A, Leocata F, Cajola F,Servello D, Allegranza A, Broggi G.(1994) Low-grade glial tumors in basal ganglia and thalamus: natural history and biological reappraisal. Neurosurg, 35: 817-21.
96
113. van Veelen ML, Avezaat CJ, Kros JM,van Putten W, Vecht C. (1998) Supratentorial low-grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psych, 64: 581-7.
114. Müller W, Áfra D, Schröder R. (1977) Supratentorial reccurences of gliomas.
Morphological studies in relation to time intervals with asztrocitomas.Acta Neurochir, 37: 75-91.
115. Philippon JH, Clemeceau SH, Fauchon FH, Foncin JF.(1993) Supratentorial low-grade asztrocitomas in adult. Neurosurg, 32: 554-9.
116. Laws ER, Taylor WF, Clifton MB, Okazaki H.(1984) Neurosurgical management of low-grade asztrocitomas of the cerebral hemispheres. JNeurosurg, 61: 665-73.
117. Morantz NA.(1987) Radiation therapy in the treatment of cerebral asztrocitoma.
Neurosurg, 20: 9975-82.
118. Shaw EG, Daumas-Duport C, Scheithauer BW,Gilbertson DT, O'Fallon JR, Earle JD, Laws ER Jr, Okazaki H. (1989) Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg, 70: 853-861.
119. Lunsford LD, Somaza S, Kondziolka D, Flickinger JC.(1995) Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic asztrocitoma.
J Neurosurg. 82(4): 523-529.
120. Zentner J, Meyer B, Stangl A, Schramm J.(1996) Intrinsic tumors of the insula: a prospective surgical study of 30 patients. J Neurosurg, 85: 263-271.
121. Vanaclocha V, Saiz-Sapena N, Garcia-Casasola C.(1997) Surgical treatment of insular gliomas. Acta Neurochir, 139: 1126-35.
122. van den Bent MJ, Afra D, de Witte O,Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB; EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council.(2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, 366(9490):
985-990.
97
13. Köszönetnyilvánítás
Köszönettel tartozom Áfra Dénes Tanár Úrnak és Sipos László Főorvos Úrnak,akik mellett kezdtem el foglalkozni neuroonkológiával, továbbá Banczerowski Péter Professzor Úrnak töretlen támogatásáért és biztatásáért és Czirják Sándor Tanár Úrnak szakmai útmutatásáért, valamint családomnak, akik végig támogattak a munkám során.